Dyne Therapeutics Announces $200M Public Offering

The latest announcement is out from Dyne Therapeutics ( (DYN) ).

On June 30, 2025, Dyne Therapeutics announced an underwritten public offering of 24,242,425 shares of its common stock at $8.25 per share, expected to generate gross proceeds of $200 million. The offering, managed by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, is anticipated to close around July 2, 2025, and could raise up to $215.2 million if additional shares are purchased. The proceeds aim to fund Dyne’s operations into the third quarter of 2027, enhancing its financial runway and supporting its strategic initiatives in the neuromuscular disease therapeutics sector.

The most recent analyst rating on (DYN) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Spark’s Take on DYN Stock

According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.

Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.

To see Spark’s full report on DYN stock, click here.

More about Dyne Therapeutics

Dyne Therapeutics is a clinical-stage company focused on developing therapeutics for genetically driven neuromuscular diseases. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

Average Trading Volume: 2,661,695

Technical Sentiment Signal: Sell

Current Market Cap: $1.09B

For an in-depth examination of DYN stock, go to TipRanks’ Overview page.